Hikma Pharmaceuticals accelerates revenue growth with strong branded medicines performance in first half of 2026

Hikma Pharmaceuticals reports a 4 per cent increase in first-half revenue, driven by a 15 per cent rise in branded medicines, as strategic initiatives and new product launches bolster prospects for 2026.

Hikma Pharmaceuticals said first-half revenue rose 4 per cent, or 3 per cent at constant exchange rates, to $1.728bn, compared with $1.658bn in the first half of 2025, as strong growth in branded medicines offset stable revenue in injectables and Hikma Rx. The group said the result was in line with expectations.

Chief executive Said Darwazah said he was pleased to report “good performance” in the first half, including 9 per cent growth in core operating profit. He added that Hikma had made good progress on its strategic priorities, including new product launches, pipeline development, partnerships and manufacturing efficiencies, and reaffirmed full-year guidance.

Hikma said it continued to strengthen the foundations for long-term sustainable growth during the first half of 2026, with its $250m share buyback programme proceeding well. Regional leadership teams are driving commercial and operational improvements across North America, Europe and MENA.

The branded medicines business grew 15 per cent, supported by chronic-disease treatments and new launches in key markets in the Middle East. Hikma said 14 of 15 new products launched across its five main markets through R&D or partnerships were either first to market or first generic alternatives.

Injectables performed in line with expectations, with steady US core businesses, good growth in Europe and the rest of the world, and strong performance in MENA, although this was partly affected by supply disruption at one of Hikma’s licensing partners. Hikma Rx, which supplies the US retail market, delivered strong core operating profit growth.

The group reiterated its 2026 revenue guidance for branded medicines of 6 per cent to 8 per cent, injectables of low single-digit growth, and Hikma Rx of broadly flat revenue, while confirming full-year group revenue growth guidance of 2 per cent to 4 per cent at constant exchange rates. Hikma also said Tobias Hustler will join the board as an independent non-executive director from 7 August 2026.